A Study to Evaluate Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Phase 1/2
416
about 6.1 years
18+
13 sites in AL, FL, IA +8
About this study
Researchers are testing the safety, tolerability, drug levels, and early effectiveness of a treatment called BMS-986507 when combined with other medications in adults who have advanced solid tumors. The trial will last for approximately 2 years.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BMS-986507
- 2.Take Nivolumab
- 3.Take Osimertinib
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells), osimertinib, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion, oral (Oral Tablet)
Primary: Number of DLTs that occur during the DLT evaluation period, Number of participants with AEs leading to death, Number of participants with AEs leading to discontinuation, Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) critera, Number of participants with adverse events (AEs), Number of participants with serious adverse events (SAEs)
Secondary: Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)), Area under the serum concentration-time curve within a dosing interval (AUC(TAU)), Maximum observed serum concentration (Cmax), Objective response rate (ORR), Time of maximum observed concentration (Tmax)
Oncology